Ashley Alexander

The University of Texas MD Anderson Cancer Center Senior Physician Liaison. Tweets are my own

[Ashley Alexander @AshAlexander44]

What an amazing day for the 10th Annual @MDAndersonNews Boot Walk! “Who ya gonna call? Patients Access!” Team Walkbusters! #endcancer

[UT MD Anderson @UTMDAnderson]

“It was among the easier questions I’ve ever been asked as a cancer doctor,” says our Dr. Van Morris of being asked to walk Sheri Shaw James down the aisle. @VanMorrisMD @DrEmmaHolliday #ColorectalCancer #EndCancer

[Naoto T Ueno, MD, PhD @teamoncology]

Join me as I present “New HER2 Classification Impact to the Management of Low HER2 Metastatic Breast Cancer” at the @MDAndersonNews Physician Advisory Council!
Virtual Meeting Today at 5:30 – 6:30 p.m. CST.

Register here: https://t.co/ZWrqL3KanE

[Jean-Nicolas Vauthey MD @VautheyMD]

Great @UTHealthSASurg San Antonio Liver Cancer Symposium 👏 Kudos to @DrSukeshiArora Dr Cigarroa and @UnivTransplant for the excellent program 💯 @hernandezliver @MDAndersonNews #oncsurgery

[Ashley Alexander @AshAlexander44]

It’s a great day to be at #SOHO22 and representing @MDAndersonNews! Make sure to stop by our booth in the exhibitor hall. #Endcancer #SOHO2022

[UT MD Anderson @UTMDAnderson]

Happening now at #ASCO22: Meet Nobel Laureate Dr. James Allison and Dr. Padmanee Sharma at booth 6122. @JimAllisonPhD @PamSharmaMDPhD #EndCancer

[UT MD Anderson @UTMDAnderson]

MD Anderson is committed to being a world-leader in cancer care, research, prevention and education. Our Strategy lays the framework for our future.

Hear from MD Anderson President Dr. Peter WT Pisters today from 11 a.m. to 1 p.m. at booth 6122. @PPisters #ASCO22 #EndCancer

[Ashley Alexander @AshAlexander44]

I may be bias but we have some of the most amazing faculty!!! Those smiles light up the future of #cancer care!

[Vivek Subbiah, MD @VivekSubbiah]

⭐️ All the cancer breakthroughs of the last 5 years in one picture 🎯Do we go to the moon ? Mars ? No we plan to go to another galaxy to #endcancer ! Anything is possible working together with these amazing teammates @MDAndersonNews @AACR #AACR22 #precisionmedicine #immunotherapy

[UT MD Anderson @UTMDAnderson]

Dr. Amir Jazaeri serves as a discussant of the results a Phase II trial investigating durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer in a clinical trials plenary session at #AACR22. @AmirJazaeri #EndCancer

[UT MD Anderson @UTMDAnderson]

From AACR: Our Dr. Tina Cascone shares results from
the Phase II NeoCOAST clinical trial, which found immunotherapy plus durvalumab outperforms
durvalumab alone in the neoadjuvant setting for early-stage non-small-cell lung cancer: https://t.co/8qTncSVy7p
#AACR22 #EndCancer

[Ashley Alexander @AshAlexander44]

A wonderful inspirational article on one of my beloved colleagues @S_Champagne1960.
Multiple myeloma survivor and employee: ‘MD Anderson really is the best’ https://t.co/6g1efqrK8x

[Ashley Alexander @AshAlexander44]

Health care providers, join us tonight’s Physician Advisory Council meeting, where we will be joined by MD Anderson President Dr. Peter WT Pisters. The virtual event is from 6-7 p.m. CST. Register here: https://t.co/ZWGSnANhJC @PPisters #EndCancer

[UT MD Anderson @UTMDAnderson]

“This study shows axi-cel to be effective and suggests patients may receive durable benefit from receiving the treatment before being exposed to other therapies,” says our Dr. Sattva Neelapu of the ZUMA-12 findings: https://t.co/5EFge9ejJp #ASH21 #CART #EndCancer

[UT MD Anderson @UTMDAnderson]

HMA plus venetoclax resulted in higher response rates and longer survival than chemotherapy for patients with treated secondary AML, according to data presented by our Dr. Sangeetha Venugopal at #ASH21 (abstract 794): https://t.co/xnob4DXYKC @drsangeetmd #EndCancer

[UT MD Anderson @UTMDAnderson]

What does #ASH21 mean for patients?

Watch to hear our Dr. Naveen Pemmaraju share the significance of the meeting and how it ultimately leads to better patient care. ⁦⁦@doctorpemm⁩ #EndCancer

[Musa Yilmaz, MD @MusaYilmazMD]

Want learn more 👉 Join us tomorrow (12/13), AML session #613 (4:30-6:00pm), discussing our frontline triplet (HMA+VEN+FLT3i) experience in older/unfit FLT3 mutated AML - a pooled analysis @Daver_Leukemia @TapKadia @NicholasShortMD @doctorpemm @DrHKantarjian @MDAndersonNews

[UT MD Anderson @UTMDAnderson]

Watch to hear Dr. Christopher Flowers share key takeaways from MD Anderson’s clinical trials being presented at #ASH21.

View the data: https://t.co/TEzmYV8e6F @ChrisRFlowersMD #EndCancer

[UT MD Anderson @UTMDAnderson]

“These treatments available to us today, hopefully will become standard of care years down the road,” says our Dr. Elias Jabbour of clinical trials for leukemia. #ASH21 #EndCancer

[UT MD Anderson @UTMDAnderson]

In poster session 632 at #ASH21, he’ll discuss dose modification dynamics of ponatinib in patients with chronic myeloid leukemia (abstract 2550): https://t.co/Qy7W8hiF5K #EndCancer

[UT MD Anderson @UTMDAnderson]

Meet our Dr. William Wierda by visiting booth 1212 today from 3-4 p.m. ET.

Discuss the latest in CLL, including results from the CAPTIVATE clinical trial that examined first-line treatment with ibrutinib plus venetoclax. @wwierda #ASH21 #EndCancer